Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVB-101 phase 1/2 study in frontotemporal dementia with progranulin mutations
NL-OMON60308Phase 2Not yet recruiting
- Sponsor
- AviadoBio
- Start
- Sep 2023
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AVB-101 in Progranulin-Associated Frontotemporal Dementia (FTD-GRN), sponsored by AviadoBio. Primary endpoints: Adverse events and serious adverse events, Vital signs, ECG, physical and neurological examinations and 4 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
AVB-101
03
Conditions
Progranulin-Associated Frontotemporal Dementia (FTD-GRN)
Beyond the preview
Go deeper on NL-OMON60308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60308.